Why carry out this study?

The management of patients affected by moderate-to-severe psoriasis may be challenging, in particular in patients with serious infectious diseases.

Therefore, the infectious risk as well as the presence of a severe infectious disease should be considered in treatment decisions.

What was learned from the study?

Patients should be screened for tuberculosis, hepatitis B and C, and HIV before starting the majority of systemic treatments for psoriasis.

Our review evaluated the management of patients affected by moderate-to-severe psoriasis with serious infectious disease.

Each of the currently approved systemic drug for psoriasis (conventional systemic drugs, biologics, oral small molecules) is characterized by a unique safety profile which should be considered before starting therapy.